RNN says two-thirds of total patients now enrolled in clinical trial Print E-mail
By M.E.Garza   
Thursday, 05 May 2011 08:00

Rexahn Pharmaceuticals, Inc. (Amex: RNN), one of our favorite clinical stage biotech investment plays, today announced that it has enrolled two-thirds of the total patients needed for its Phase IIb clinical trial to study the safety and efficacy of Serdaxin to treat major depressive disorder (MDD).

RNN began enrollment for the study earlier this year and plans to enroll a total of 300 patients. The trial is being conducted at 40 sites in the United States.

We believe that once RNN reports preliminary results of the study, shares will be trading at multiples of current levels. Soon after our initial report, filed in February of 2010, the company was approached by six different pharmaceutical companies seeking to partner based on early clinical data from their study of Serdaxin- a drug candidate described as a potential market leading CNS therapeutic that activates dual enhancement of serotonin and dopamine levels in the brain.

Instead of accepting an offer detailed with $20 million up front and coupled with over $1 billion in milestone payments, financial advisors convinced the company’s conservative management team to finish Phase II studies of the drug as a treatment for major depressive disorder. Other experts suggested that by doing so, Rexahn would return armed with stronger data and a bigger bargaining chip later this year.

"Serdaxin’s Phase IIb clinical trial enrollment is on schedule, and we are on track to report preliminary results by the end of this year," said Rick Soni, President of Rexahn.

In April, Jonathan Moreland, author of Profit From Legal Insider Trading repoied that Ahn Chang Ho, the CEO of RNN purchased $391,432 worth of shares in RNN in the open market. The stock has been eating through some overhang which resulted from a recent March 31st financing. Since that time, prices have been building a base around the $1.17 mark.

Like Clinical Data’s Viibryd, Serdaxin has all the markings of a blockbuster; but in addition, it has shown the potential to treat multiple CNS illnesses including depression, anxiety, and other mood disorders and that clearly makes it even more attractive to Big Pharma. In addition, Serdaxin has demonstrated neuroprotective activity that may have the unique ability to not only treat symptoms, but also slow the progression of neurodegenerative diseases, such as Parkinson’s and Alzheimer’s disease.

Serdaxin works on the pleasure center of the brain and helps raise both dopamine and serotonin levels. Scientists believe the drug will continue to show excellent efficacy and that its safety profile is solid.
In addition to Serdaxin, Dr. Chang Ahn, Rexahn’s Chairman and Chief Executive Officer is convinced his team can push two additional and equally promising Phase II compounds, Archexin and Zoraxel, to market.

The Serdaxin Phase IIb clinical trial is designed as a randomized, double blind, placebo-controlled study with three treatment arms. The primary endpoint is the change from baseline on the Montgomery-Asberg Depression Rating Scale ("MADRS").

Rexahn has multiple clinical programs planned for investigating Serdaxin in the treatment of anxiety disorders, Parkinson’s disease, Alzheimer’s disease and neurodegenerative illnesses, neuroprotection and biodefense uses.

This continues to be one of the most undervalued biotechs with multiple blockbuster-type drugs in their late-stage pipeline. A Phase I study looking at the drug candidate’s abilities against Parkinson’s should be announced soon.

Disclosure: None

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus